Expanding frontiers, transforming cancer treatment

Your day-by-day guide to ASCO
1 – 5 June 2012

McCormick Place Convention Center
Chicago, Illinois, USA
Congress site plan
## Key presentations

### Product key

<table>
<thead>
<tr>
<th>A</th>
<th>Avastin</th>
</tr>
</thead>
<tbody>
<tr>
<td>E</td>
<td>Erivedge</td>
</tr>
<tr>
<td>H</td>
<td>Herceptin</td>
</tr>
<tr>
<td>MT</td>
<td>MabThera</td>
</tr>
<tr>
<td>MM</td>
<td>Onartuzumab (MetMAb)</td>
</tr>
<tr>
<td>P</td>
<td>Pertuzumab</td>
</tr>
<tr>
<td>T</td>
<td>Tarceva</td>
</tr>
<tr>
<td>T</td>
<td>Trastuzumab emtansine (T-DM1)</td>
</tr>
<tr>
<td>X</td>
<td>Xeloda</td>
</tr>
<tr>
<td>Z</td>
<td>Zelboraf</td>
</tr>
</tbody>
</table>
POSTER DISCUSSION SESSION
Gynecologic Cancer

Session time: 13.00 - 17.00
Presentation time: 16.30 - 17.30
Venue: E450a
Venue: E354a

Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): results from OCTAVIA. (A. Gonzalez-Martin; Poster Board 6, Abstract # 5017)
ORAL ABSTRACT SESSIONS

Gynecologic Cancer

Session time: 15.00 – 18.00  
Presentation time: 15.00 – 15.15
Venue: E354b

Randomised phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platin-based chemotherapy for ovarian carcinoma. A Gynecological Cancer Intergroup and EORTC-GCG study. (I. Vergote; Abstract # LBA5000)

AURELIA, a randomized phase III trial evaluating bevacizumab (BEV) combined with chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC). (E. Pujade-Lauraine; Abstract # LBA5002)
Expression of p16, ERCC1 and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy and erlotinib - a phase II randomized trial. (M.C. Austin; Poster Board 5, Abstract # 5515)

Results from a phase 1b study of trastuzumab emtansine (T–DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. (S. Modi; Poster Board 18, Abstract # 528)

Cardiac safety in a phase II study of trastuzumab emtansine (T–DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer. (C.T. Dang; Poster Board 22, Abstract # 532)
**Breast Cancer – HER2/ER**

Session time: 13.15 - 17.15  
Presentation time: 16.45 - 17.45  
Venue: E450a  
Venue: E Hall D2

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. (M.S. Ewer; Poster Board 23, Abstract # 533)

**GENERAL POSTER SESSION**

**Lung Cancer – Non-small Cell Metastatic**

Session time: 13.15 – 17.15  
Venue: S Hall A2

Skin toxicity associated with outcome to erlotinib in non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study. (C. Buges; Poster Board 44H, Abstract # 7542)

Session time: 13.15 – 17.15  
Venue: S Hall A2

Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small-cell lung cancer (NSCLC) patients (p) in the EURTAC study. (C.E. Carcereny; Poster Board 44F, Abstract # 7540)
Cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer in the NCIC CTG BR.21 study: time course and correlation. (R. Perez-Soler; Poster Board 48G, Abstract # 7573)

AvaALL: open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous non-small cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT). (C. Gridelli; Poster Board 53F, Abstract # TPS7612)

ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). (K. Park; Poster Board 53H, Abstract # TPS7614)
Lung Cancer – Non-small Cell Metastatic

Session time: 13.15 – 17.15

The MetLUNG study: a randomized, double-blind, phase III study of onartuzumab (MetMAb) + erlotinib versus placebo + erlotinib in patients with advanced, Met-positive non-small cell lung cancer (NSCLC). (D.R. Spigel; Poster Board 54B, Abstract # TPS7616)
Breast Cancer – HER2/ER

Session time: 08.00 – 12.00 Venue: S Hall A2

Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA. (J. Baselga; Poster Board 8H, Abstract # 597)

Session time: 08.00 – 12.00 Venue: S Hall A2

A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu over-expressing metastatic breast cancer (HER2+ MBC): a trial of the Eastern Cooperative Oncology Group (E1105). (C.L. Arteaga; Poster Board 9H, Abstract # 605)

Session time: 13.15 – 17.15 Venue: E450a

Quality of Life Assessment in CLEOPATRA, a Phase III Study Combining Pertuzumab with Trastuzumab and Docetaxel in Metastatic Breast Cancer. (J. Cortes; Poster Board 9A, Abstract # 598)

Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy

Session time: 08.00 – 12.00 Venue: S Hall A2

Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study. (I. Schrader; Poster Board 24D, Abstract # 1077)
PLENARY SESSION

Plenary Session Including Science of Oncology Award and Lecture

Session time: 13.00 – 16.00
Presentation time: 13.45 – 14.00
Venue: N Hall B1

Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) vs capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (K. Blackwell; Abstract # LBA1)

Session time: 13.00 – 16.00
Presentation time: 14.45 – 15.00
Venue: N Hall B1

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. (M. Rummel; Abstract # 3)
Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial. (C. Tournigand; Abstract # LBA3500)

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV + CT: results of a randomised phase III intergroup study (TML study). (D.E. Arnold, Abstract # CRA3503)
POSTER DISCUSSION SESSION

Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Session time: 08.00 - 12.00  
Presentation time: 11.30 - 12.30  
Venue: E450a

SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/radiotherapy (RT) followed by consolidation docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC). (A.J. Wozniak; Poster Board 10, Abstract # 7018)

The SELECT study: a multicenter phase II trial of adjuvant erlotinib in resected EGFR mutation-positive NSCLC. (J.W. Neal JW; Poster Board 2, Abstract # 7010)

Cancer Prevention/Epidemiology

Session time: 08.00 - 12.00  
Presentation time: 11.30 - 12.30  
Venue: S102

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. (A.M. Brufsky; Poster Board 15, Abstract # 1526)
**GENERAL POSTER SESSION**

**Melanoma/Skin Cancers**

**Session time:** 08.00 – 12.00  
**Venue:** S Hall A2

**Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): Erivance BCC study update.** (A. Sekulic; Poster Board 36E, Abstract # 8579)

**Metastatic basal cell carcinoma: Differences in survival by site of spread.** (McCusker M; Poster Board 37C, Abstract # 8585)

**Gynecologic Cancer**

**Session time:** 08.00 – 12.00  
**Venue:** S Hall A2

**An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.** (C. Aghajanian; Poster Board 19F, Abstract # 5054)
Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF<sup>V600E</sup>-mutated melanoma. (P.B. Chapman; Abstract # 8502)

Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma. (J.A. Sosman; Abstract # 8503)

Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck. (R. Martins; Abstract # 5503)
Lung Cancer – Non-small Cell Metastatic

Session time: 15.00 – 18.00
Presentation time: 15.15 – 15.30
Venue: E Hall D2

TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. (M. C. Garassino; Abstract # LBA7501)

POSTER DISCUSSION SESSION

Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy

Session time: 13.15 - 17.15
Presentation time: 16.45 - 17.45
Venue: E450b
Venue: N Hall B1

Association of a compact 13-gene VEGF-signature is associated with OS in E2100. (S. Willis; Poster Board 19, Abstract # 1027)
GENERAL POSTER SESSION

Gastrointestinal (colorectal cancer)

Session time: 08.00 – 12.00
Venue: S Hall A2

Efficacy and safety of bevacizumab in metastatic colorectal cancer (mCRC): pooled analysis from randomized controlled trials (RCTs). (N.C. Tebbutt; Poster Board 36C, Abstract # 3614)

A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating onartuzumab (MetMAb) in combination with mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. (J.C. Bendell; Poster Board 39E, Abstract # TPS3640)

Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicentre study. (S. Yalcin; Poster Board 28C, Abstract # 3565)
Gastrointestinal (colorectal cancer)

Session time: 08.00 – 12.00 Venue: S Hall A2

Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110 / ML22011 randomized, phase III trial. (C.A. Giessen; Poster Board 39D, Abstract # TPS3639)

Leukemia, Myelodysplasia, and Transplantation

Session time: 13.15 – 17.15 Venue: S Hall A2

Pharmacokinetics (PK) and pharmacodynamics (PD) of rituximab administered by faster infusion in patients with previously untreated diffuse large B-cell (DLBCL) or follicular lymphoma (FL). (M. Brewster; Poster Board 21B, Abstract # 6591)

Tumor Biology

Session time: 11.30 - 12.30 Venue: S100a

Dynamic contrast-enhanced MRI versus 18FMISONIDAZOL-PET/CT to predict pathological response in bevacizumab-based neoadjuvant therapy in breast cancer. (J.G. Foncillas; Poster Board 5, Abstract # 10512)
Lung Cancer – Non-small Cell Metastatic

Session time: 08.00 - 12.00  Venue: E450a
Presentation time: 11.30 - 12.30  Venue: E354a

A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. (T. Mok; Poster Board 9, Abstract # 7519)

Session time: 08.00 - 12.00  Venue: E450a
Presentation time: 11.30 - 12.30  Venue: E354a

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). (C. Zhou; Poster Board 10, Abstract # 7520)

Session time: 08.00 - 12.00  Venue: E450a
Presentation time: 11.30 - 12.30  Venue: E354a

Phase II Trials of Erlotinib (OSI-774)(E) and Bevacizumab (B) in Advanced (Adv) Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (adenoBAC), or in Never-Smokers with Primary Adv NSCLC Adenocarcinoma (adenoCa). (H.L. West; Poster Board 7, Abstract # 7517)
### Lung Cancer – Non-small Cell Metastatic

**Session time:** 08.00 - 12.00  
**Presentation time:** 11.30 - 12.30  
**Venue:** E450a

EGFR compound mutants discriminate survival to erlotinib in non-small-cell lung cancer (NSCLC) patients (p) in the EURTAC study. (R. Rosell; Poster Board 12, Abstract # 7522)

### Tumor Biology

**Session time:** 08.00 - 12.00  
**Presentation time:** 11.30 - 12.30  
**Venue:** S102

Dynamic contrast-enhanced MRI versus 18FMISONIDAZOL-PET/CT to predict pathological response in bevacizumab-based neoadjuvant therapy in breast cancer. (J.G. Foncillas; Poster Board 5, Abstract # 10512)
Swissôtel Chicago
323 East Wacker Drive
Chicago, IL, 60601–9722
Phone: + 1–312–565–05–65
   Breakfast: Restaurant Geneva
     Mon-Fri: 06.30 – 10.30
     Sat-Sun: 06.30 - 12.00

Double Tree Magnificent Mile
300 E. Ohio Street
Chicago, IL, 60611
Phone: + 1-312-787-6100
   Breakfast: Private Banquet Room
     June 1 to 5: 06.30 - 09.00
     May 30/31 & June 6: Restaurant Markethouse
     06.00 - 11.00

W Lake Shore
644 N Lake Shore Dr
Chicago, IL, 60611, United States
Phone: + 1–312–943–92–00
   Breakfast: ALTITUDE Ballroom, 33rd Floor
     06.30 – 10.30

Hotel Palomar Chicago
505 North State Street
Chicago, IL, 60654
Phone: + 1-312-755-9703
   Breakfast: Private Banquet Room
     June 1: Contemporary Room
     June 2 to 5: Gallery Ballroom
     Mon-Sun: 06.00 - 09.30
**SpringHill Suites Chicago Downtown/River North**

410 North Dearborn Street  
Chicago, IL, 60654  
Phone: +1-312-567-1234  

Breakfast: Breakfast Room (lobby area)  
Mon-Fri: 06.30 - 09.00  
Sat-Sun: 07.30 - 10.00

---

**Hyatt Regency McCormick Place**

2233 S. Martin L. King Dr.  
Chicago, IL, 60616  
Phone: +1–312–567–12–34

Breakfast: Restaurant Shore  
06.30 - 11.00